Gender differences in autoimmunity: molecular basis for estrogen effects in systemic lupus erythematosus

Int Immunopharmacol. 2001 Jun;1(6):1009-24. doi: 10.1016/s1567-5769(01)00046-7.

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disease that occurs primarily in women (9:1 compared to men). Estrogen is a female sex hormone that acts on target cells through specific receptor proteins and alters the rate of transcription of target genes. Experiments in our laboratory have shown that calcineurin steady-state mRNA levels and phosphatase activity increase when estrogen is cultured with SLE T cells. This estrogen-dependent increase is dose-dependent, hormone-specific and temporally regulated. Estrogen receptor antagonism by ICI 182,780 inhibits the increase in calcineurin mRNA and phosphatase activity, while cycloheximide has no effect suggesting that new protein synthesis is not required. Reverse transcription and polymerase chain amplification indicate that estrogen receptor-alpha and estrogen-beta are expressed in human T cells. However, calcineurin does not respond to estrogen stimulation in T cells from normal females, males and lupus males. Taken together, these results indicate a differential function of the estrogen receptor in women with lupus. A model is proposed that suggests estrogen, acting through the estrogen receptor, enhances T cell activation in women with lupus resulting in amplified T-B cells interactions, B cell activation and autoantibody production.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Autoimmunity / genetics
  • Autoimmunity / immunology
  • Autoimmunity / physiology*
  • Calcineurin / biosynthesis
  • Calcineurin / genetics
  • Estrogens / pharmacology*
  • Female
  • Humans
  • Lupus Erythematosus, Systemic / immunology*
  • Male
  • RNA, Messenger / biosynthesis
  • RNA, Messenger / genetics
  • Sex Characteristics

Substances

  • Estrogens
  • RNA, Messenger
  • Calcineurin